



Dedicated to Saving Lives
by Transforming At-home
Cancer Detection

Corporate Overview – January 2024

Safe Harbor

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; expectations for development of new or improved products and services; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts.



Mainz BioMed Overview

Colorectal cancer screening – A significant opportunity



- **\$10bn+ global CRC market** (3rd most-commonly diagnosed cancer; 2nd leading cause of cancer death globally)
- Ability to move into large, adjacent areas, including pancreatic cancer and other GI cancers

First Generation CRC screening Test launched in Europe (ColoAlert®)

- Highly efficacious, at-home, stool-based screening test for early colorectal cancer (CRC) detection
- Combines a FIT test for detection of human hemoglobin with the **PCR results of specific tumor DNA markers**
- Marketed as a **CE-IVD product in Europe since 2021**

Disruptive, decentralized business model



- Kit-based solution that allows the testing to be done in any lab across the United States.
- All competitors using CLIA laboratory based centralized solutions that require large investments to broadly commercialize the product nationally
- Enables the sale of ColoAlert® internationally

Strong team

- Experienced diagnostics team, formerly Roche, Abbott or Qiagen; took the company public in 2021
- **64 employees** with headquarters in Mainz, Germany
- Strong Medical Advisory Board with renowned scientific and oncology experts

Disruptive next-gen product (in development)



- Expanding current test to add novel, proprietary **mRNA** biomarkers to increase the detection of advanced adenomas
- Early detection of advanced adenomas (precancerous lesions) could drastically reduce or even eliminate cancer
- Two ongoing clinical trials with data reported in 2023; **planning to initiate recruitment for FDA PMA pivotal study in mid 2024**

Strong intellectual property position

- Valuable IP position, with **new IP in development**
- Trade secret portfolio

Advantages of our Decentralized Business Model

CLIA lab companies



Why did we choose a decentralized model:

- Differentiation from all other advanced US based CRC screening companies
- Ability to partner with large labs (e.g. LabCorp/Quest/Sonic/Arup) to leverage their large physician network
 - *Lower investment in building our own commercial channels*
 - *Quicker path to profitability, lower COGS than CLIA labs*
 - *Lab partners are excited about the opportunity to participate in the >\$10b US CRC screening market*
- Partnering opportunities with large Diagnostic players (Roche, Abbott, and others currently in the screening market or interested in entering the screening market)
- Centralized - CLIA lab business models don't work internationally

Our Current Flagship
Product

ColoAlert®

Our Current Flagship Product – ColoAlert®

A PCR based CRC early detection stool test: simple, fast, accurate and non-invasive



- Highly accurate test (92% specificity, 85% sensitivity)¹
- 98% patient satisfaction – easy product to use²
- Designed to offer affordable CRC screening solutions
- Identifies tumor DNA next to blood in stool samples
- Available through online shop, corporate health programs and networks of lab partners



DNA stabilization tube



FIT tube




¹ Published by: Dollinger MM et al. Clin Lab 10/2018

² 98% overall satisfaction with ColoAlert® in our internal customer survey.

ColoAlert® – Sample Processing and Reporting Process

DNA biomarkers provide highly efficacious early CRC detection test



DNA BIOMARKERS

- Quantification total human DNA (qPCR)
- Mutation analysis - KRAS Codon 12/13
- Mutation analysis - BRAF Codon 600

Commercialization Achievements 2023

Strategy

Lab Partnerships

Employer Corporate Health Programs

Online Shop



Expansion of Lab Partnerships in Germany

- Targeting their physician and patient networks



LIMBACH GRUPPE




Expansion to New Markets

- United Kingdom
- Spain
- Portugal
- Italy
- United Arab Emirates
- Austria
- Poland
- Romania
- Israel



Targeting BKK and PKV

- Inclusion of three new companies in corporate health program
- More than 400 companies targeted since the launch of BGM program
- PKV campaign targeting 16,000 private physicians



Targeting patients and physicians

- Re-brushed online shop
- PKV landing page and HCP education
- Pilot campaign with pharmacies in Germany




Next Generation CRC Screening Test

(under development)

Early Identification of Colorectal Cancer (CRC) Saves Lives

Clinical progression from colorectal polyp to cancer



- Almost all colorectal cancers develop from polyps over time
- With increasing time of a polyp being present, the risk of malignancy increases
- Early screening has the potential to dramatically impact the treatment and prevention of CRC, and ultimately save lives

The goal of Mainz Biomed's next generation screening test is to improve the detection of advanced adenomas (precancerous lesions)

Impact of AA sensitivity on CRC Mortality and Incidents Rates

Including AAs detection in screening tests significantly reduces both incidence and mortality

- Discussion of CMS decision memo on thresholds of 74% sensitivity, 90% specificity for blood-based screening for CRC. No thresholds set for detection of AA.

If a screening tests in 45yr olds and above resulted in:

- **21% sensitivity for AA:**

- ▶ Reduction of CRC incidence by 30%
- ▶ Reduction of CRC mortality by 47%


- **76% sensitivity for AA:**

- ▶ Reduction in CRC incidence by 57%
- ▶ Reduction in CRC mortality by 67%

Ladabaum U, et al. Counting Advanced Precancerous Lesions as True Positives When Determining Colorectal Cancer Screening Test Specificity, JNCI: Journal of the National Cancer Institute, Volume 114, Issue 7, July 2022, Pages 1040-1043 <https://doi.org/10.1093/jnci/djac027>

Next Generation Screening Test – Including mRNA Biomarkers

Combination of DNA & mRNA biomarkers expected to create leading product for AA and CRC detection



Next Generation Clinical Validation and Trials

2023-2024

2024 - 2025

■ Feasibility trials

- ColoFuture (Germany, Norway & Denmark)
 - 662 subjects across 9 study sites; top line feasibility data reported September 13, 2023; full data presented October 18, 2023
- eAArly DETECT (US)
 - 450 subjects across 25 study sites; topline feasibility data report on Dec 5, 2023

■ IRB approved trial

- ReconAAsense (US)
 - Pivotal FDA PMA study,
 - ~15,000 subjects across 150 study sites

Highly Promising Colorectal Cancer (CRC) Clinical Trial Results


- Mainz Biomed has recently completed two successful clinical trials for CRC screening
- Combined, the trials collected data from 474 participants across 28 sites
- ColoFuture (EU) and eAArly DETECT (US) both assessed the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, the company's efficacious CRC screening test on the market in Europe
- The mRNA biomarkers in combination with the FIT test enabled high CRC sensitivity & specificity but also remarkably high advanced adenoma (AA) sensitivity
- The industry-leading performance has the potential to enable the transition from CRC early cancer screening to CRC prevention with AA screening

	Mainz Biomed	
	ColoFuture	eAArly DETECT
CRC Sensitivity	94%	97%
CRC Specificity	97%	97%
AA Sensitivity	80%	82%
AA Specificity	95%	97%
Location	EU	US
# of Participants	220	254
# of Study Sites	7	21


Source: Company websites and press releases.

Competition: CRC and Advanced Adenoma (AA) Sensitivity and Specificity

CRC sensitivity



Advanced Adenoma sensitivity




* > 10,000 subjects screening studies

* > 10,000 subjects screening studies

Product Pipeline & Corporate Update

ReconAAsense Timeline and Future Product Pipeline



Pipeline Development – PancAlert

AN EARLY DETECTION PANCREATIC
CANCER SCREENING TEST based on real-
time PCR-based detection of biomarkers
in stool samples

In early research stage



- As GenX individuals age into their 40s and 50s they become part of the age group recommended to begin testing for CRC and more

Potential combo test with ColoAlert®

- Research program supported by a grant from Germany's Federal Ministry for Education and Research



Microba Partnership:

- Microba and Mainz Biomed to conduct a pilot research project utilizing Microba's proprietary metagenomic sequencing technology and bioinformatic tools to potentially discover novel microbiome biomarkers for pancreatic cancer detection
- Multiple diagnostic opportunities including discovery of diagnostic and prognostic biomarkers by the explorative partnership with Microba
- Faecal microbiota-based screening also applicable to other gastrointestinal cancers

Leadership Team

Highly Accomplished Dx Executives



Guido Baechler
CEO



William Caragol
CFO



Darin Leigh
CCO



Dr. Frank Krieg-Schneider
CTO



Dr. Chris Von Torne
COO



Philipp Freese
CBO



Dr. Moritz Eidens
CSO



Jane Edwards
VP, Clinical Affairs



Stefan Erlach
Head of People



Leading Industry and Clinical Advisors

Renowned Scientific and Oncology Experts



Dr. Heiner Dreismann
Chairman of Board



Dr. Michele Pedrocchi
Strategic Advisor



Dr. Rainer Metzger
Strategic Advisor



Karen L. Richards
Regulatory Advisor



Dr. Soren Thestrup-Nielsen
Clinical Advisor



Dr. Kim Turgeon
Clinical Advisor



Dr. Douglas Rex
Clinical Advisor



Dr. Timothy Wang
Clinical Advisor




Dr. Matthias Dollinger
Clinical Advisor



Dr. Frank Cockerill
Clinical Advisor



Upcoming Milestones – Six Months



Summary Financial Data

(unaudited), in \$	Nine months ended September 30	
	2023	2022
REVENUE		
ColoAlert® Revenue	\$680,718	\$336,596
Cost of Revenue	305,793	190,741
GROSS PROFIT	374,925	145,855
OPERATING EXPENSES		
	55.1%	43.3%
Research and Development	7,591,168	1,702,491
Sales and Marketing	5,207,795	3,393,858
General and Administration	7,630,246	13,104,566
TOTAL OPERATING EXPENSES	20,429,209	18,200,915
OPERATING LOSS	(20,054,284)	(18,055,060)
NON-CASH ADJUSTMENTS TO NET LOSS	3,957,221	8,402,663
ADJUSTED EBITDA	\$(16,097,063)	\$(9,652,397)
BALANCE SHEET DATA:		
	September 30, 2023	December 31, 2022
Cash Balance	\$9,320,381	\$17,141,775
Total Debt	8,253,074	1,983,787
Stockholders' Equity	3,449,368	14,096,067

(i) As of November 15, 2023

(ii) Including ordinary share equivalents

Capitalization:

Nasdaq Ticker: MYNZ

Basic Shares O/S : 21,165,482 ⁽ⁱ⁾ ⁽ⁱⁱ⁾

Fully Diluted Shares O/S: 30,492,540 ⁽ⁱ⁾ ⁽ⁱⁱ⁾

Market Cap (Fully Diluted): \$36,895,973 ⁽ⁱ⁾



Analyst Coverage:

Ross Osborn, Cantor Fitzgerald
Yi Chen, HC Wainright
Justin Walsh, Jones Trading



Investment Highlights



Highly-differentiated
flagship product (ColoAlert®)

Significant market opportunity



Disruptive, decentralized business
model

Developing next-gen product



Strong intellectual
property position

Strong team



Executed milestones to
accelerate commercial roll-out



THANK YOU



CORPORATE PRESENTATION

Mainz Biomed N.V.
Robert-Koch-Straße 50
55129 Mainz, Germany

Tel: +49 (0) 6131 / 55428-60
Inquiries: info@mainzbiomed.com
it@mainzbiomed.com